CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
| Autor: | Minoru Takada, Nobuhide Takifuji, Kaoru Matsui, Masahiro Fukuoka, S. Negoro, S. Kudoh, Noriyuki Masuda, Yoko Kusunoki, S Kishimoto, Kazuhiko Nakagawa |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Irinotecan Gastroenterology Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Aged Cisplatin Chemotherapy business.industry Respiratory disease Middle Aged medicine.disease Antineoplastic Agents Phytogenic Surgery Diarrhea Treatment Outcome Oncology Toxicity Camptothecin Female Non small cell medicine.symptom business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 10:1775-1780 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1992.10.11.1775 |
| Popis: | PURPOSE The purpose of this study was to determine the maximum-tolerated dose and the dose-limiting toxicities of CPT-11, a new derivative of camptothecin, in combination with a fixed dose of cisplatin in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Twenty-seven previously untreated patients with stage IIIB or IV NSCLC were assessable for toxicity, and 26 were assessable for response. The initial dose of CPT-11 was 30 mg/m2 given as a 90-minute intravenous (IV) infusion on days 1, 8, and 15 in combination with cisplatin (80 mg/m2 IV on day 1) given every 4 weeks. The dose of CPT-11 was escalated in increments of 10 mg/m2 until severe or life-threatening toxic effects were observed. RESULTS Significant toxicity was infrequent up to 60 mg/m2 of CPT-11. The maximum-tolerated toxicity was reached at a dose of 70 mg/m2. Three of six patients either had leukocyte count nadirs of less than 2,000/microL or experienced grade 4 diarrhea during the first cycle of therapy at 70 mg/m2. The major toxic effects were leukopenia and diarrhea. There were 14 partial responses (54%) among the 26 patients. CONCLUSIONS A combination of CPT-11 and cisplatin seems to be effective against NSCLC with acceptable toxicities. The recommended dose for phase II studies is 60 mg/m2 of CPT-11 on days 1, 8, and 15, and 80 mg/m2 of cisplatin on day 1 every 4 weeks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|